tbuckley/cabot-search huggingface dataset:
306 Decr2 regulates tumor cell ferroptosis and is required for immunotherapy efficacy
Authors: Shuyin Li, Thomas Gajewski, Shuyin Li, Emily Higgs
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Checkpoint blockade therapies have transformed the landscape of cancer care. Durable clinical responses have been observed in a subset of patients. However, many patients do not respond, and understanding the mechanisms underlying tumor resistance to checkpoint blockade drugs could potentially expand clinical benefit. We therefore performed an unbiased CRISPR library screen to identify novel gene alterations sufficient to mediate resistance to T cell-mediated killing. Methods B16.SIY cells were transduced with a genome-scale gRNA lentivirus to generate loss of function mutants. In vitro-primed CD8+ T cells isolated from 2C/Rag2–/– TCR transgenic mice specific for the SIY antigen were co-cultured with transduced B16.SIY tumor cells. Resistant cells were collected and targeted genes were identified by sequencing the gRNAs. The gene encoding Decr2, a peroxisomal 2,4-dienoyl-CoA reductase, was identified. To investigate the role of Decr2 in tumor growth and immune responses in vivo, the Decr2 knock-down or Decr2 overexpressed tumors were transplanted into C57BL/6 mice for studies of anti-PD-L1 efficacy and immune response analysis. Based on a hypothesized role in ferroptosis, RNA-seq was performed and lipid reactive oxygen species were quantified. Results Decr2 mutants were relatively resistant to CD8+ T cell killing in vitro. In vivo, Decr2 knock-down tumors showed almost complete loss of anti-PD-L1 efficacy, without affecting early T cell priming or immune cell infiltration. However, tumor-infiltrating T cells failed to expand following anti-PD-L1 therapy in Decr2 knock-down tumors. RNA-seq analysis revealed upregulation of ferroptosis-related genes in Decr2-deficient tumor cells, and these tumor cells were relatively resistant to ferroptosis-inducers in vitro. Decr2 knock-down cells also showed defective induction of lipid ROS in response to CD8+ T cells in vitro, or when analyzed following anti-PD-L1 treatment ex vivo. Analysis of tumor RNA-seq data from human melanoma patients treated with checkpoint blockade revealed decreased Decr2 levels in non-responding patients. Conclusions Our results identify tumor cell-expressed Decr2 as novel regulator of ferroptosis and implicate the process of ferroptosis as a major mechanism of immune-mediated tumor cell killing in vivo. Pharmacologic strategies to facilitate tumor cell ferroptosis could have therapeutic utility.
约翰 F B 史密斯
Authors: 肯·斯图尔特
Journal: BMJ (2021)

约翰 F B 史密斯 在邓迪和阿伯丁皇家医院接受培训，然后在格拉斯哥教学医院接受培训。 1973 年，他被任命为福尔柯克和地区皇家医院的顾问医生。 1976 年，他搬到斯特灵皇家医院，在那里工作直到 2002 年退休，之后他继续在……
Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation Study
Authors: Julia Z. Xu, Anna Conrey, Ingrid Frey, Eveline Gwaabe, Laurel A Menapace, Laxminath Tumburu, Maureen Lundt, Quan Li, Kristen Glass, Varsha Iyer, Heidi Mangus, Charles Kung, Lenny Dang, Penelope A. Kosinski, Peter Hawkins, Neal Jeffries, William Eaton, Swee Lay Thein
Journal: Blood (2021)
The Role of Face Masks in the Recognition of Emotions by Preschool Children
Authors: Juliane Schneider, Vania Sandoz, Lucile Equey, Joanne Williams-Smith, Antje Horsch, Myriam Bickle Graz
Journal: JAMA Pediatrics (2021)

This cohort study of children in a single day care examines their ability to correctly identity emotions of caregivers with and without face masks.
Natriuresis‐guided therapy in acute heart failure: rationale and design of the <scp>Pragmatic Urinary Sodium‐based treatment algoritHm</scp> in <scp>Acute Heart Failure</scp> (<scp>PUSH‐AHF</scp>) trial
Authors: Jozine M. ter Maaten, Iris E. Beldhuis, Peter van der Meer, Jan A. Krikken, Jenifer E. Coster, Wybe Nieuwland, Dirk J. van Veldhuisen, Adriaan A. Voors, Kevin Damman
Journal: European Journal of Heart Failure (2021)

Insufficient diuretic response frequently occurs in patients admitted for acute heart failure (HF) and is associated with worse clinical outcomes. Recent studies have shown that measuring natriuresis early after hospital admission could reliably identify patients with a poor diuretic response during hospitalization who might require enhanced diuretic treatment. This study will test the hypothesis that natriuresis-guided therapy in patients with acute HF improves natriuresis and clinical outcomes.The Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) is a pragmatic, single-centre, randomized, controlled, open-label study, aiming to recruit 310 acute HF patients requiring treatment with intravenous loop diuretics. Patients will be randomized to natriuresis-guided therapy or standard of care. Natriuresis will be determined at set time points after initiation of intravenous loop diuretics, and treatment will be adjusted based on the urinary sodium levels in the natriuresis-guided group using a pre-specified stepwise approach of increasing doses of loop diuretics and the initiation of combination diuretic therapy. The co-primary endpoint is 24-h urinary sodium excretion after start of loop diuretic therapy and a combined endpoint of all-cause mortality or first HF rehospitalization at 6 months. Secondary endpoints include 48- and 72-h sodium excretion, length of hospital stay, and percentage change in N-terminal pro brain natriuretic peptide at 48 and 72 h.The PUSH-AHF study will investigate whether natriuresis-guided therapy, using a pre-specified stepwise diuretic treatment approach, improves natriuresis and clinical outcomes in patients with acute HF.
Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds
Authors: Melinda A. L. Day, Philipp Sergeev, Caroline A. Heckman, Anna Schinzel, Nikolaus D. Obholzer, Charles Y. Lin, Pavan Kumar, Jorge DiMartino, Douglas C. Saffran
Journal: Blood (2021)
Abstract 13877: Financial Hardship From Medical Bills Among Non-Elderly Adults With Obesity in the US
Authors: Shiwani Mahajan, Javier Valero Elizondo, Rohan Khera, Mohamad Taha, Isaac Acquah, Miguel Cainzos Achirica, Harlan M Krumholz, Khurram Nasir
Journal: Circulation (2021)

Introduction: Obesity is a growing public health challenge in the US and carries a heavy economic toll. Previous work has detailed the overall health expenditures in this population, but we lack a current understanding on how these expenditures translate into financial hardship. We aimed to assess the financial hardship from medical bills, as well as other cost-related healthcare shortcomings experienced by those with obesity. Methods: We used the National Health Interview Survey (2013-18), a US nationally representative sample, to assess financial hardship from medical bills - difficulty paying or unable to pay at all (and consequences, including high financial distress, foregone/delayed care due to cost, and cost-related medication nonadherence) in non-elderly adults (18-65 years [i.e., those without universal coverage]) across different BMI strata. BMI was categorized as normal (18.5-24.9 kg/m 2 ), overweight (25-29.9 kg/m 2 ), obesity classes 1 (30-34.9 kg/m 2 ), 2 (35-39.9 kg/m 2 ), and 3 (≥ 40 kg/m 2 ). Results: Among 139,521 surveyed individuals, 12,129 (weighted 8.5%) had class 3 obesity, representing 16 million non-elderly adults annually. A total of 38.0% of non-elderly adults with class 3 obesity reported having financial hardship from medical bills, compared with 24.7% among those with normal weight. Compared with adults with normal weight, those with class 3 obesity had higher odds of financial hardship from medical bills (OR 1.53, 95% CI 1.44-1.64), and among those with any financial hardship, higher odds of its consequences, including high financial distress (OR 1.13, 95% CI 1.01-1.25) and cost-related medication nonadherence (OR 1.16, 95% CI 1.02, 1.32). Conclusion: Non-elderly adults with class 3 obesity had 50% higher odds of financial hardship from medical bills, compared with those with normal weight, along with higher odds for its consequences, like financial distress and cost-related medication nonadherence.
ECG-Based Deep Learning and Clinical Risk Factors to Predict Atrial Fibrillation
Authors: Shaan Khurshid, Samuel Friedman, Christopher Reeder, Paolo Di Achille, Nathaniel Diamant, Pulkit Singh, Lia X. Harrington, Xin Wang, Mostafa A. Al-Alusi, Gopal Sarma, Andrea S. Foulkes, Patrick T. Ellinor, Christopher D. Anderson, Jennifer E. Ho, Anthony A. Philippakis, Puneet Batra, Steven A. Lubitz
Journal: Circulation (2021)

Background: Artificial intelligence (AI)–enabled analysis of 12-lead ECGs may facilitate efficient estimation of incident atrial fibrillation (AF) risk. However, it remains unclear whether AI provides meaningful and generalizable improvement in predictive accuracy beyond clinical risk factors for AF. Methods: We trained a convolutional neural network (ECG-AI) to infer 5-year incident AF risk using 12-lead ECGs in patients receiving longitudinal primary care at Massachusetts General Hospital (MGH). We then fit 3 Cox proportional hazards models, composed of ECG-AI 5-year AF probability, CHARGE-AF clinical risk score (Cohorts for Heart and Aging in Genomic Epidemiology–Atrial Fibrillation), and terms for both ECG-AI and CHARGE-AF (CH-AI), respectively. We assessed model performance by calculating discrimination (area under the receiver operating characteristic curve) and calibration in an internal test set and 2 external test sets (Brigham and Women’s Hospital [BWH] and UK Biobank). Models were recalibrated to estimate 2-year AF risk in the UK Biobank given limited available follow-up. We used saliency mapping to identify ECG features most influential on ECG-AI risk predictions and assessed correlation between ECG-AI and CHARGE-AF linear predictors. Results: The training set comprised 45 770 individuals (age 55±17 years, 53% women, 2171 AF events) and the test sets comprised 83 162 individuals (age 59±13 years, 56% women, 2424 AF events). Area under the receiver operating characteristic curve was comparable using CHARGE-AF (MGH, 0.802 [95% CI, 0.767–0.836]; BWH, 0.752 [95% CI, 0.741–0.763]; UK Biobank, 0.732 [95% CI, 0.704–0.759]) and ECG-AI (MGH, 0.823 [95% CI, 0.790–0.856]; BWH, 0.747 [95% CI, 0.736–0.759]; UK Biobank, 0.705 [95% CI, 0.673–0.737]). Area under the receiver operating characteristic curve was highest using CH-AI (MGH, 0.838 [95% CI, 0.807 to 0.869]; BWH, 0.777 [95% CI, 0.766 to 0.788]; UK Biobank, 0.746 [95% CI, 0.716 to 0.776]). Calibration error was low using ECG-AI (MGH, 0.0212; BWH, 0.0129; UK Biobank, 0.0035) and CH-AI (MGH, 0.012; BWH, 0.0108; UK Biobank, 0.0001). In saliency analyses, the ECG P-wave had the greatest influence on AI model predictions. ECG-AI and CHARGE-AF linear predictors were correlated (Pearson r : MGH, 0.61; BWH, 0.66; UK Biobank, 0.41). Conclusions: AI-based analysis of 12-lead ECGs has similar predictive usefulness to a clinical risk factor model for incident AF and the approaches are complementary. ECG-AI may enable efficient quantification of future AF risk.
Triple Combination of Ruxolutinib, Nilotinib and Prednisone Is Safe and Shows Promising Activity for the Treatment of Myelofibrosis Patients, Results of a Phase Ib Clinical Trial (RUNIC)
Authors: Rosa Ayala, Rafael Alonso Fernández, Valentín Garcia Gutierrez, Alberto Alvarez-Larran, Santiago Osorio, Jose M. Sanchez, Gonzalo Carreño Gomez-Tarragona, María Teresa Gómez-Casares, Antonia Duran, Joaquín Martínez-López
Journal: Blood (2021)
A Quality-Adjusted Survival (Q-TWiST) Analysis to Assess Benefit-Risk of Acalabrutinib Versus Idelalisib/Bendamustine Plus Rituximab or Ibrutinib Among Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients
Authors: John F. Seymour, Priyanka Gaitonde, Ugochinyere Emeribe, Ling Cai, Anthony R. Mato
Journal: Blood (2021)
Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study
Authors: Rachel Cusatis, Irena Tan, Claire Piehowski, Idayat Akinola, Emma Crawford, Juliana Craig, Aline Thiengmany, Matthew J. Frank, David B. Miklos, Nirav N. Shah, Anita D'Souza, Jennifer M Knight, Lori Muffly, Kathryn E Flynn, Surbhi Sidana
Journal: Blood (2021)
Targeting Metabolic Vulnerabilities in Primary Effusion Lymphoma Using the Novel Nucleoside Analog 6-Eti
Authors: Jouliana Sadek, Jan Krumsiek, Tuo Zhang, Barbara Coan, Maite Ibañez de Garayo, Tanner Dalton, Sara Yahyaei, Herman Van Besien, Ethel Cesarman
Journal: Blood (2021)
Abstract 13741: Impact Of Cannabis Use Disorder On Outcomes Of Hospitalization Due To Acute Myocardial Infarction
Authors: Abhinay Theli, Shrikanth Sampath, Cecilia Gadaga, Bahredin Abdella, SHILPI SHARMA, Naima A Rahim, Krupa Patel, Darshi Desai, Saral Desai, Achint Patel
Journal: Circulation (2021)

Background: The prevalence of cannabis use disorder (CUD) has increased in the US especially following its legalization in various states. Few smaller studies have reported that CUD has been associated with increased Acute Myocardial Infarction (AMI) but reduced mortality. There is limited and inconclusive literature on the impact of concurrent CUD on AMI outcomes especially in the younger population. Hypothesis: To estimate the impact of CUD on hospitalizations due to AMI in the young population from the largest available database. Methods: We derived a study sample from the National Inpatient Sample (NIS) for the years 2007-2018. Hospitalizations due to AMI among the age group of 18-49 were identified using previously validated ICD-9-CM/ICD-10-CM. Cannabis use disorder and other diagnosis of interests were identified by ICD-9/10-CM codes. Primary outcome of interest was in-hospital mortality. We then utilized the Cochran Armitage trend test and multivariable survey logistic regression modeling to analyze impact of CUD on AMI outcomes. Results: Out of a total 819,354 hospitalizations due to AMI among the young population, 33,488 (4.1%) had concurrent CUD. AMI patients with CBD were younger (40 vs 44 years; p&lt;0.01), male (78.1.2% vs 71.6%; p&lt;0.01) and African American (35.2% vs 15.8%; p&lt;0.01). CUD was also associated with lower utilization of PCI (OR 0.9; 95%CI 0.9-0.9; p:0.03). There was no significant difference in CABG utilization, mechanical ventilation requirement and cardiac arrest in patients with and without CUD. In-hospital mortality was lower in the CUD group as compared to non-CUD (1.3 vs 1.7; p&lt;0.01). After adjusting with patient and hospital level characteristics, comorbidities and confounding factors, CUD was associated with lower in-hospital mortality (OR 0.7; 95%CI 0.6-0.9; p&lt;0.01) and discharge to facilities (OR 0.9; 95%CI 0.8-0.9; p:0.02). Conclusion: Our study found lower PCI utilization as well as lower in-hospital mortality and discharge to facilities among the young AMI patients with CUD. Our study cannot establish causal relationship and further studies are required for in-depth exploration and identify possible mechanisms of cannabis on myocardial infarction and its severity.
Restoring Iron Homeostasis in Pts Who Achieved Transfusion Independence after Treatment with Betibeglogene Autotemcel Gene Therapy: Results from up to 7 Years of Follow-up
Authors: Alexis A. Thompson, Franco Locatelli, Evangelia Yannaki, Mark C. Walters, John B. Porter, Suradej Hongeng, Andreas E. Kulozik, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Marina Cavazzana, John E.J. Rasko, Lin Du, Richard A. Colvin, Janet L. Kwiatkowski
Journal: Blood (2021)
IL-1 Via IRAK1/4 Sustains Acute Myeloid Leukemia Stem Cells Following Treatment and Relapse
Authors: Tzu-Chieh Ho, Hiroki Kawano, Mark W. LaMere, Naxin Guo, Yu-Chiao Chiu, Jian Wang, Craig T. Jordan, Nikolay V. Dokholyan, Laura M. Calvi, Rakesh Kumar Singh, Michael W. Becker
Journal: Blood (2021)
Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML
Authors: Sangeetha Venugopal, Tapan M. Kadia, Farhad Ravandi, Courtney D. DiNardo, Naval Daver, Gautam Borthakur, Marina Konopleva, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Abhishek Maiti, Musa Yilmaz, Ghayas C. Issa, Kelly S. Chien, Sherry A. Pierce, Hagop Kantarjian, Nicholas J. Short
Journal: Blood (2021)
Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for <i>JAK2 V617F</i> Myeloproliferative Neoplasms (MPNs)
Authors: Ghaith Abu-Zeinah, Silvana Di Giandomenico, Tatiana Cruz, Daniel Choi, Elwood Taylor, Ellen Ritchie, Richard T. Silver, Joseph Scandura
Journal: Blood (2021)
Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)
Authors: Thomas Schroeder, Matthias Stelljes, Maximilian Christopeit, Eva Schmidt, Christoph Scheid, Jan-Henrik Mikesch, Christina Rautenberg, Paul Jäger, Nadja Drusenheimer, Udo Holtick, Stefan Klein, Rudolf Trenschel, Rainer Haas, Ulrich Germing, Nicolaus Kröger, Guido Kobbe
Journal: Blood (2021)
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour
Authors: Thomas Yang Sun, Grace Hwang, Danielle Pancirer, Kathleen Hornbacker, Alberto Codima, Natalie S. Lui, Rishi Raj, Pamela Kunz, Sukhmani K. Padda
Journal: European Respiratory Journal (2021)

<b>DIPNECH is a rare disease that is often misdiagnosed. In this study, it primarily affected elderly white women who were non-smokers. Lung nodules could slowly progress over years to carcinoid tumours. Average growth rate per nodule was 0.8 mm per year.</b>https://bit.ly/3q1HD1k
Allogeneic, CD34 +, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease
Authors: Michael Heuser, Astrid Tschan-Plessl, Felicitas Thol, Adrian Schwarzer, Arnold Kloos, Nadine Kattre, Jakob Passweg, Kai Pinkernell, Arnold Ganser
Journal: Blood (2021)
The Absence of NLRP6 in Donor T Cells Exacerbates Gvhd
Authors: Masahiro Suto, Eri Matsuki, Masahiro Miyata, Erika Sekiguchi, Hiroya Tamaki, Isao Tawara, Daniel Peltier, Grace Chen, Kenichi Ishizawa, Pavan Reddy, Tomomi Toubai
Journal: Blood (2021)
Transcriptomic taxonomy and neurogenic trajectories of adult human, macaque, and pig hippocampal and entorhinal cells
Authors: Daniel Franjic, Mario Skarica, Shaojie Ma, Jon I. Arellano, Andrew T.N. Tebbenkamp, Jinmyung Choi, Chuan Xu, Qian Li, Yury M. Morozov, David Andrijevic, Zvonimir Vrselja, Ana Spajic, Gabriel Santpere, Mingfeng Li, Shupei Zhang, Yang Liu, Joshua Spurrier, Le Zhang, Ivan Gudelj, Lucija Rapan, Hideyuki Takahashi, Anita Huttner, Rong Fan, Stephen M. Strittmatter, Andre M.M. Sousa, Pasko Rakic, Nenad Sestan
Journal: Neuron (2021)

The hippocampal-entorhinal system supports cognitive functions, has lifelong neurogenic capabilities in many species, and is selectively vulnerable to Alzheimer's disease. To investigate neurogenic potential and cellular diversity, we profiled single-nucleus transcriptomes in five hippocampal-entorhinal subregions in humans, macaques, and pigs. Integrated cross-species analysis revealed robust transcriptomic and histologic signatures of neurogenesis in the adult mouse, pig, and macaque but not humans. Doublecortin (DCX), a widely accepted marker of newly generated granule cells, was detected in diverse human neurons, but it did not define immature neuron populations. To explore species differences in cellular diversity and implications for disease, we characterized subregion-specific, transcriptomically defined cell types and transitional changes from the three-layered archicortex to the six-layered neocortex. Notably, METTL7B defined subregion-specific excitatory neurons and astrocytes in primates, associated with endoplasmic reticulum and lipid droplet proteins, including Alzheimer's disease-related proteins. This resource reveals cell-type- and species-specific properties shaping hippocampal-entorhinal neurogenesis and function.
Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
Authors: Martin Metz, Gordon Sussman, Rémi Gagnon, Petra Staubach, Tonny Tanus, William H. Yang, Jeremy J. Lim, Holly J. Clarke, Joshua Galanter, Leslie W. Chinn, Tom Chu, Anastasia Teterina, Tracy Burgess, D. James Haddon, Timothy T. Lu, Marcus Maurer
Journal: Nature Medicine (2021)

Abstract Bruton’s tyrosine kinase (BTK) is crucial for FcεRI-mediated mast cell activation and essential for autoantibody production by B cells in chronic spontaneous urticaria (CSU). Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU. This double-blind, placebo-controlled, phase 2 trial (EudraCT ID 2016-004624-35 ) randomized 93 adults with antihistamine-refractory CSU to 50 mg daily, 150 mg daily and 200 mg twice daily of fenebrutinib or placebo for 8 weeks. The primary end point was change from baseline in urticaria activity score over 7 d (UAS7) at week 8. Secondary end points were the change from baseline in UAS7 at week 4 and the proportion of patients well-controlled (UAS7 ≤ 6) at week 8. Fenebrutinib efficacy in patients with type IIb autoimmunity and effects on IgG-anti-FcεRI were exploratory end points. Safety was also evaluated. The primary end point was met, with dose-dependent improvements in UAS7 at week 8 occurring at 200 mg twice daily and 150 mg daily, but not at 50 mg daily of fenebrutinib versus placebo. Asymptomatic, reversible grade 2 and 3 liver transaminase elevations occurred in the fenebrutinib 150 mg daily and 200 mg twice daily groups (2 patients each). Fenebrutinib diminished disease activity in patients with antihistamine-refractory CSU, including more patients with refractory type IIb autoimmunity. These results support the potential use of BTK inhibition in antihistamine-refractory CSU.
Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD)
Authors: Yuntian Ding, Lei Wang, Ming Ni, Wenjie Gong, Sanmei Wang, Brigitte Neuber, Maria-Luisa Schubert, Tim Sauer, Angela Hückelhoven-Krauss, Thomas Luft, Ute Hegenbart, Stefan Schönland, Volker Eckstein, Jishi Wang, William Hermann Krüger, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt
Journal: Blood (2021)
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease
Authors: Jennifer R. Kramer, Yamini Natarajan, Jianliang Dai, Xian Yu, Liang Li, Hashem B. El‐Serag, Fasiha Kanwal
Journal: Hepatology (2021)

In patients with NAFLD, those with type 2 diabetes mellitus (DM) have a high risk of progression to HCC. However, the determinants of HCC risk in these patients remain unclear.
Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial
Authors: Matthew W Jenner, Andrew Hall, Sian E Faustini, Alexandra Pitchford, Ruth M. de Tute, Sadie Roberts, Emma Ingleson, Kristian M Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Guy Pratt, Gordon Cook, Roger G Owen, Sarah R Brown, Mark T Drayson, Martin F. Kaiser
Journal: Blood (2021)